CONTEXT: Previous investigators have reported discrepancies between hematologic, marrow morphologic, and cytogenetic responses to imatinib mesylate among patients with chronic myeloid leukemia (CML).
discrepancies between hematologic, marrow morphologic, and cytogenetic responses
imatinib mesylate